A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
← catalyst calendarNCT07135973 · readout in 376 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
26estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-10 | estimated | When the study began enrolling |
| Primary completion | 2027-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Graft Versus Host Disease
Intervention
- Drug: Belumosudil — also filed as SAR445761, Rezurock
Primary outcome
what the primary-completion date above is the date OFDrug related Grade ≥ 3 treatment emergent adverse events (TEAE)
measured From baseline to 24 weeks
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed